# OnCo record keymed (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/keymed/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "keymed" ;
  schema:name "Keymed Biosciences (KYM Biosciences)"@en ;
  schema:description "Chinese biotech whose joint venture KYM Biosciences created the Claudin 18.2 ADC CMG901, licensed to AstraZeneca in 2023."@en ;
  schema:url <https://onco.cc/companies/keymed/>, <https://www.keymedbio.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-enters-license-agreement-with-kym-biosciences-for-cmg901-a-claudin-182-antibody-drug-conjugate.html> ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cldn18-2/> ;
  onco:drugs <https://onco.cc/drugs/cmg901/> ;
  onco:trials <https://onco.cc/trials/nct05299424/>, <https://onco.cc/trials/nct05263960/>, <https://onco.cc/trials/nct07019779/> .